[1] Gusev E, Solomatina L, Zhuravleva Y, et al. The pathogenesis of endstage renal disease from the standpoint of the theory of general pathological processes of inflammation[J]. Int J Mol Sci, 2021, 22(21):11453.
[2] Cerullo D, Rottoli D, Corna D, et al. Add-on cyclic angiotensin-(1-7) with cyclophosphamide arrests progressive kidney disease in rats with ANCA associated glomerulonephritis[J]. Cells, 2022, 11(15): 2434.
[3] Khan MAH, Hwang SH, Barnett SD, et al. Multitarget molecule, PTUPB, to treat diabetic nephropathy in rats[J]. Br J Pharmacol, 2021, 178(22): 4468-4484.
[4] Du Q, Fu YX, Shu AM, et al. Loganin alleviates macrophage infiltration and activation by inhibiting the MCP-1/CCR2 axis in diabetic nephropathy[J]. Life Sci, 2021, 272(1): 118808.
[5] Wang MR, Zhang XJ, Liu HC, et al. Matrine protects oligodendrocytes by inhibiting their apoptosis and enhancing mitochondrial autophagy[J]. Brain Res Bull, 2019, 153(1): 30-38.
[6] Mahzari A, Li S, Zhou X, et al. Matrine protects against MCD-induced development of NASH via upregulating HSP72 and downregulating mTOR in a manner distinctive from metformin[J]. Front Pharmacol, 2019, 10(1): 405.
[7] Li WW, Wang TY, Cao B, et al. Synergistic protection of matrine and lycopene against lipopolysaccharideinduced acute lung injury in mice[J]. Mol Med Rep, 2019, 20(1): 455-462.
[8] Khan A, Shal B, Naveed M, et al. Matrine ameliorates anxiety and depression-like behaviour by targeting hyperammonemia-induced neuroinflammation and oxidative stress in CCl4 model of liver injury[J]. Neurotoxicology, 2019, 72(1): 38-50.
[9] Xu Y, Lin H, Zheng W, et al. Matrine ameliorates adriamycin-induced nephropathy in rats by enhancing renal function and modulating Th17/Treg balance[J]. Eur J Pharmacol, 2016, 791(1): 491-501.
[10] Lin J, Ouyang H, Liang ChL, et al. Effects of total glucosides of Paeony on kidney protection in rats with chronic glomerulonephritis[J]. Traditional Chinese Drug Research and Clinical Pharmacology, 2021, 32(10): 1425-1430. (in Chinese)
林劲, 欧阳辉, 梁春玲, 等. 白芍总苷对慢性肾小球肾炎模型大鼠的肾脏保护作用及机制研究[J]. 中药新药与临床药理, 2021, 32(10): 1425-1430.
[11] Zhao X, Lu Y, Li S, et al. Predicting renal function recovery and short-term reversibility among acute kidney injury patients in the ICU: comparison of machine learning methods and conventional regression[J]. Ren Fail, 2022, 44(1):1326-1337.
[12] Zhang YB, Zhang XL, Chen NH, et al. Four matrine-based alkaloids with antiviral activities against hbv from the seeds of sophora alopecuroides[J]. Org Lett, 2017,19(2):424-427.
[13] Xiao Y, Ma D, Wang H, et al. Matrine suppresses the er-positive mcf cells by regulating energy metabolism and endoplasmic reticulum stress signaling pathway[J]. Phytother Res, 2017, 31(4): 671-679.
[14] Kant S, Kronbichler A, Sharma P, et al. Advances in understanding of pathogenesis and treatment of immunemediated kidney disease: a review[J]. Am J Kidney Dis, 2022, 79(4): 582-600.
[15] Wu WB, Chen W, Lin Y. Analysis of immune function in patients with chronic glomerulonephritis[J]. Experimental and Laboratory Medicine, 2021, 39(6): 1434-1436. (in Chinese)
吴文冰, 陈雯, 林一. 慢性肾小球肾炎患者免疫功能分析[J]. 实验与检验医学, 2021, 39(6): 1434-1436.
[16] Uchida T, Ito S, Kumagai H, et al. Roles of natural killer T cells and natural killer cells in kidney injury[ J]. Int J Mol Sci, 2019, 20(10): 2487.
[17] Ruszkowski J, Lisowska KA, Pindel M, et al. T cells in IgA nephropathy: role in pathogenesis,clinical significance and potential therapeutic target[J]. Clin Exp Nephrol, 2019, 23(3): 291-303.
[18] Zou Y, Zhao Q, Zhang X, et al. The immunosuppressive effects and mechanisms of loureirin B on collagen-induced arthritis in rats[J]. Front Immunol, 2023, 14: 1094649.
[19] Singh S, Anshita D, Ravichandiran V. MCP-1: function, regulation, and involvement in disease[J]. Int Immunopharmacol,2021, 101(1): 107598.
[20] Yoshimura T. The production of monocyte chemoattractant protein-1 (MCP-1)/CCL2 in tumor microenvironments[J]. Cytokine, 2017, 98(1): 71-78.
[21] Xu L, Sharkey D, Cantley LG. Tubular GM-CSF promotes late MCP1/CCR2-mediated fibrosis and inflammation after ischemia/reperfusion injury[J]. J Am Soc Nephrol,2019, 30(10): 1825-1840.
[22] Moadab F, Khorramdelazad H, Abbasifard M. Role of CCL2/CCR2 axis in the immunopathogenesis of rheumatoid arthritis: latest evidence and therapeutic approaches[J]. Life Sciences, 2021, 269(1): 119034.
[23] Lefèvre L, Iacovoni JS, Martini H, et al. Kidney inflammaging is promoted by CCR2 macrophages and tissue-derived micro-environmental factors[J]. Cell Mol Life Sci, 2021, 78(7): 3485-3501.
[24] Kanemitsu N, Kiyonaga F, Mizukami K, et al. Chronic treatment with the (iso-)glutaminyl cyclase inhibitor PQ529 is a novel and effective approach for glomerulonephritis in chronic kidney disease[J]. Naunyn Schmiedebergs Arch Pharmacol, 2021, 394(4): 751-761.
|